Evidence map›Paper›PMID 37230533›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

A VISION Substudy of Reader Agreement on

Phillip H Kuo, Don C Yoo, Ryan Avery, Marc Seltzer, Jeremie Calais, James Nagarajah, Wolfgang A Weber, Wolfgang P Fendler, Michael S Hofman, Bernd J Krause and 6 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03511664 (VISION), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03511664 phase3completednot on this map

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

TypeinterventionalSponsorEndocyteRan2018 to 2023Enrolled861ConditionsProstate CancerArms177Lu-PSMA-617, Best supportive/best standard of care
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Lancet (London, England) · 2024
    Trial
  2. QuantitativeRadiology · 2024
    Trial
  3. Interreader and Intrareader Reproducibility ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Trial
  4. Pivotal Phase 3 Theranostic Trials: Future Indications.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Review
  5. Article
  6. Article
  7. Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  8. The Role of Nuclear Medicine in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2025
    Review
  9. Molecules (Basel, Switzerland) · 2025
    Review
  10. Article
  11. [EJNMMI reports · 2024
    Article
  12. Impact of PSMA PET on Prostate Cancer Management.Current treatment options in oncology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 4 countries.

Phillip H KuoUniversity of Arizona, Tucson, Arizona; pkuo@email.arizona.edu.
Don C YooWarren Alpert Medical School of Brown University, Providence, Rhode Island.
Ryan AveryNorthwestern University, Evanston, Illinois.
Marc SeltzerGeisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
James NagarajahDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Wolfgang A WeberTUM School of Medicine, Technical University of Munich, Munich, Germany.
Wolfgang P FendlerDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.
Michael S HofmanCancer Imaging, Prostate Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Bernd J KrauseRostock University Medical Center, Rostock, Germany.
Marcia BrackmanNovartis Pharmaceuticals Corporation, Indianapolis, Indiana.
Euloge KpameganNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Samson GhebremariamNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Taylor BensonNovartis Pharmaceuticals Corporation, St. George, Utah.
Ana M CatafauAdvanced Accelerator Applications, Geneva, Switzerland; and.
Ayse T KendiMayo Clinic, Rochester, Minnesota.
Novartis (United States) · USAdvanced Applications (United States) · USBrown University · USDartmouth College · USMayo Clinic · USNorthwestern University · USRadboud University Nijmegen · NLTechnical University of Munich · DEThe University of Melbourne · AUUniversity of Arizona · USUniversity of Duisburg-Essen · DEUniversity of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[

Indexed as

Positron Emission Tomography Computed TomographyProstatic NeoplasmsDipeptidesGallium IsotopesGallium RadioisotopesHeterocyclic Compounds, 1-RingHumansMaleProstate-Specific AntigenReproducibility of ResultsRetrospective StudiesDipeptidesgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesHeterocyclic Compounds, 1-RingProstate-Specific AntigenPSMA-617PET/CTprostate cancerPSMA

Identifiers

PMID37230533
PMCPMC10394308
OpenAlexW4378214169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.